More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…
Read More
What if psilocybin works about as well for depression as an SSRI?
The fervent hope surrounding classic psychedelics as a revolutionary treatment for depression may be tempering, with recent data suggesting that…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…
Read More
Autobahn Therapeutics Secures FDA Fast Track Designation for Elunetirom in Bipolar Depression
Autobahn Therapeutics has announced a significant milestone in its development of elunetirom, a novel central nervous system (CNS)-directed thyroid hormone…
Read More
Blood-Based Epigenetic Markers of Immune Cell Aging Reveal New Pathways for Identifying Depression Symptoms
A landmark study published in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences has unveiled a significant…
Read More
Blood-Based Epigenetic Markers of Immune Cell Aging Reveal New Pathways for Precision Depression Diagnosis and Treatment
The landscape of psychiatric medicine is undergoing a fundamental shift as researchers move away from purely symptomatic assessments toward objective…
Read More
Advanced Blood Analysis of Immune Cell Aging Offers New Pathway for Objective Depression Diagnosis and Precision Mental Health Care
The landscape of psychiatric medicine is undergoing a significant shift as researchers move closer to replacing subjective symptom reporting with…
Read More
McGill University Researchers Identify Specific Brain Cells Linked to Depression in Landmark Study
A groundbreaking study led by researchers at McGill University and the Douglas Research Centre has fundamentally altered the scientific understanding…
Read More
First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
For decades, successive waves of antidepressants have promised relief to millions suffering from mood disorders, yet the landscape for those…
Read MoreYOU MAY HAVE MISSED
